Infantile Hemangioma With Minimal or Arrested Growth : Epidemiology, Clinical Characteristics and Evolution

Comparing Epidemiological and Clinical Characteristics of Infantile Hemangioma With Minimal or Arrested Growth (IH-MAG) and Classic Infantile Hemangioma : a Retrospective Study

Infantile hemangioma (IH) is the most common vascular tumor of infancy, characterized by its clinical history. Absent at birth or present under the form of a premonitory mark, they display a rapid proliferative phase starting in the first weeks of life. Then, after a plateau phase, they slowly involute. However, a subtype of IH named "abortive", "minimal or arrested growth", "reticular" or "telangiectatic" hemangioma differs from typical IH because it doesn't have a proliferative component, or only a minimal one. This subtype of hemangioma has been recently described and data are lacking regarding its proportion among infantile hemangioma and its differences with "classic" infantile hemangioma. The aim of this study is to estimate the proportion of abortive hemangioma among infantile hemangioma. Also, the investigators aim to compare the clinical characteristics of "classic" infantile hemangiomas and abortive hemangiomas. Lastly, investigators wished to study the evolution of abortive hemangioma.

Study Overview

• Status: Completed
• Conditions: Hemangioma, Capillary

• Study Type: Observational
• Enrollment (Actual): 224

Contacts and Locations

Study Locations

• France
  • Grand-Est
    • Nancy, Grand-Est, France, 54000
      • CHRU de Nancy

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 day to 18 years (ADULT, CHILD)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

- Children between 0 and 18 years old followed in the dermatology department of CHRU de Nancy between January 2014 and December 2020 presenting with one or more infantile hemangioma

Description

Inclusion Criteria:

• Children between 0 and 18 years old
• Followed in the dermatology department of CHRU de Nancy between January 2014 and December 2020
• Presenting with one or more infantile hemangioma

Exclusion Criteria:

- Those whoes guardian does not want his data to be collected in this study

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Infantile hemangioma with minimal or arrested growth; Epidemiological and clinical characteristics of infantile hemangioma with minimal or arrested growth.
Classic infantile hemangioma; Epidemiological and clinical characteristics of classic infantile hemangioma.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of abortive hemangioma among infantile hemangioma	Proportion of abortive hemangioma among infantile hemangioma	baseline

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To compare the epidemiological characteristics between infantile hemangioma and abortive hemangioma : sex	Compare sex predominance between infantile hemangioma and abortive hemangioma	baseline
To compare the epidemiological characteristics between infantile hemangiomas and abortive hemangiomas : prematurity	Compare prematurity rates between infantile hemangiomas and abortive hemangiomas	baseline
To compare the epidemiological characteristics between infantile hemangiomas and abortive hemangiomas : birthweight	Compare birthweight between infantile hemangiomas and abortive hemangiomas	baseline
To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : localization	Compare localization between infantile hemangiomas and abortive hemangiomas	baseline
To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : treatment	le hemangiomas and abortive hemangiomaCompare treatment between infanti	baseline
To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : complications	Compare complications between infantile hemangiomas and abortive hemangioma	baseline
To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : size	Compare size (focal, extended or segmental) between infantile hemangiomas and abortive hemangioma	baseline
To study the evolution of abortive hemangioma : erythematous macule	Evaluation of the fading of erythematous macule between the stage of maximal proliferation and the last follow-up	through study completion, an average of 4 years
To study the evolution of abortive hemangioma : papules of proliferation	Evaluation of the regression of the papules of proliferation between the stage of maximal proliferation and the last follow-up	through study completion, an average of 4 years
To study the evolution of abortive hemangioma : telangiectasias	Evaluation of the fading of telangiectasias between the stage of maximal proliferation and the last follow-up	through study completion, an average of 4 years
To study the evolution of abortive hemangioma : halo of vasoconstriction	Evaluation of the fading of the vasoconstricted halo between the stage of maximal proliferation and the last follow-up	through study completion, an average of 4 years
To study the evolution of abortive hemangioma : areas of vasoconstriction	Evaluation of the fading of vasoconstricted areas between the stage of maximal proliferation and the last follow-up	through study completion, an average of 4 years
To study the evolution of abortive hemangioma : dilated veins	Evaluation of the fading of dilated veins between the stage of maximal proliferation and the last follow-up	through study completion, an average of 4 years

Collaborators and Investigators

• Sponsor: Central Hospital, Nancy, France
• Investigators: Study Director: BURSZTEJN Anne-Claire, MD, PhD, Central Hospital, Nancy, France

Study record dates

Study Major Dates

• Study Start (ACTUAL): March 23, 2021
• Primary Completion (ACTUAL): May 30, 2021
• Study Completion (ACTUAL): August 15, 2021

Study Registration Dates

• First Submitted: March 12, 2021
• First Submitted That Met QC Criteria: October 4, 2021
• First Posted (ACTUAL): October 18, 2021

Study Record Updates

• Last Update Posted (ACTUAL): October 18, 2021
• Last Update Submitted That Met QC Criteria: October 4, 2021
• Last Verified: October 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms by Histologic Type; Neoplasms; Congenital Abnormalities; Skin Abnormalities; Neoplasms, Vascular Tissue; Hemangioma, Capillary; Port-Wine Stain; Hemangioma
• Other Study ID Numbers: 2019PI221

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No